Bryn Mawr Capital Management LLC Cuts Holdings in Pfizer Inc. (NYSE:PFE)

Bryn Mawr Capital Management LLC lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,820 shares of the biopharmaceutical company's stock after selling 14,630 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Pfizer were worth $1,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Wells Trecaso Financial Group LLC raised its stake in Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock worth $416,000 after acquiring an additional 350 shares in the last quarter. Washington Trust Advisors Inc. lifted its holdings in shares of Pfizer by 0.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock valued at $1,424,000 after purchasing an additional 360 shares during the last quarter. PSI Advisors LLC boosted its position in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 385 shares during the period. Western Pacific Wealth Management LP grew its stake in Pfizer by 10.5% during the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 386 shares during the last quarter. Finally, Waddell & Associates LLC increased its position in Pfizer by 1.6% during the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock worth $723,000 after buying an additional 388 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.42 during trading on Friday, hitting $26.32. 54,560,140 shares of the company were exchanged, compared to its average volume of 38,524,395. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50 day moving average price of $26.28 and a 200 day moving average price of $27.44. The stock has a market capitalization of $149.14 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer's payout ratio is 121.99%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Guggenheim reissued a "buy" rating and set a $33.00 target price on shares of Pfizer in a research note on Monday, February 10th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 target price on the stock. Finally, StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.